Harmony Biosciences Holdings, Inc. HRMY NASDAQ · Healthcare · United States
$33.76 -0.12% -$0.04
Summary
88 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 18 USD is left as net profit.
- Revenue grew by 26% a year over the last 3 years.
- It holds more cash than debt: $647.1M against $149.1M.
- The share price is below the Bulios Fair Price.
What to watch
- Earnings per share fell by 3.0% a year over the last 3 years.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 11.1 USD for 1 USD of yearly profit. Over the last five years it was 26.8 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 40% a year over 5 years. Over the last 3 years it grew by 26% a year. For the next fiscal year analysts expect revenue to grow by 18%. Earnings per share fell by 3.0% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 26 USD
- Research and development 24 USD
- Sales and administration 28 USD
- Taxes and other 4.1 USD
- Net profit 18 USD
Net profit, industry median (Biotechnology) -11 USD
Out of every 100 USD of revenue, 18 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 3
- Sell 2
Today's price within the analysts' price targets
The average target of $48.67 is 44% above today's price. 62% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2023By product
The company reports no revenue by product.
By region
- United States 100%
United States brings in 100% of revenue.
Segments in detail